Treating HCV in Your Practice
Gilead Product Theater
Zoom Webinar • Thursday, January 20, 8:00-9:00 PM
“Treating HCV in Your Practice” presents factors contributing to the delay in achieving the World Health Organization (WHO) goal of hepatitis C virus (HCV) elimination. The United States is not on track to meet HCV elimination targets by the Year 2030. Today’s patients with HCV are often younger, found among the population of people who inject drugs, and possess certain challenges. This didactic, promotional product presentation is designed to review strategies for managing patients with HCV including pre-treatment assessments, treatment, laboratory monitoring, and post-cure management. It also brings patient challenges to light and provides data and information around Gilead’s treatment for chronic HCV, including multiple subpopulations of patients. This presentation includes an overview of the current HCV patient landscape, highlighting common characteristics and uncertainties, as well as a review of prospective clinical data sets in people treated for chronic HCV.
Learning Objectives:
- To discuss the challenges with achieving the WHO’s goal of elimination of HCV as a public health threat by 2030
- To bring to the forefront the patient challenges that are commonly seen in clinical practice in today’s patients with HCV
- To guide providers on the recommended strategies for managing patients with chronic HCV
- To inform clinicians of the highlights of relevant data for Gilead’s chronic HCV treatment, including prospective data sets in different subpopulations
Speaker: Anthony Martinez, MD | HIV Specialist/Hepatologist
As medical director of hepatology at ECMC hospital in New York, Dr. Anthony Martinez cares for outpatients with liver disease, including viral hepatitis, alcoholism, and fatty liver disease. In collaboration with the division of infectious diseases, he also evaluates and treats patients with hepatitis C virus (HCV) and HIV co-infection.
|
